Clinical Research and Development in PHEs (II): Vaccines

1st July 2020
16:00 - 17:00

Introduction

This webinar examines the way clinical research and development has addressed the needs for a vaccine in response to the COVID-19 pandemic. It addresses the following questions:

  1. What are the major scientific challenges to developing a vaccine in a short period of time to respond to a PHE (i.e. COVID-19)?
  2. Are we promising too much to the public regarding a vaccine? Are we able to promise less? more?
  3. What are the political, societal, and funding challenges to taking a rapid approach to vaccine development during a PHE?

Preparedness training webinar series

This webinar is part of our series on Preparedness Planning for Public Health Emergencies.

Find out more.

Meet the speakers

Moderator:
Professor Alan Boyd, FFPM and Immediate Past President, FPM, United Kingdom

Panellists:

  • Dr. Jakob Cramer, Head Clinical Development for the Coalition of Epidemic Preparedness Innovations (CEPI)
  • Dr. Delon Human, Health Diplomats & South African Medical Association, Switzerland & South Africa
  • Professor Jeffrey Almond, Visiting Professor of Microbiology, Oxford University, United Kingdom
  • Professor David M. Salisbury, Associate Fellow, Global Health Programme, Royal Institute for International Affairs, Chatham House, London & Chair, WHO Global Commission for Certification of Polio Eradication, United Kingdom

Biographies

  • Dr. Jakob Cramer, Head Clinical Development for the Coalition of Epidemic Preparedness Innovations (CEPI)

Jakob Peter Cramer, a medical doctor with specializations in internal medicine, tropical medicine, travel medicine and infectious diseases, joined the Coalition for Epidemic Preparedness Innovations (CEPI) as Head of Clinical Development in June 2019.

Before joining CEPI, he was Head of the Section Tropical Medicine at the Berhard Nocht Institute for Tropical Medicine (BNITM) in Hamburg, Germany, where he founded the BNCCT clinical trials unit and was part of the team to conduct more than 20 Phase 1-2-3 vaccine trials over the years against various diseases (including influenza, rabies, Japanese encephalitis, meningococcal diseases). During his academic career, he also conducted epidemiological and investigator-initiated clinical research in Africa, notably in Ghana and in Gabon. Since 2014, Jakob held the position of Medical Director, Clinical Development, Vaccine Business Unit, Takeda Pharmaceuticals International AG, Zurich, Switzerland where he was actively involved in Takeda’s polio, norovirus and dengue vaccine development programmes and gained significant experience in EMA article 58 and WHO pre-qualification procedures.

He is a lecturer at the Faculty of Medicine, University Medical Center Hamburg-Eppendorf, Germany, as well as the University of Siena MSc Course in Vaccinology, Italy, and a member of a series of infectious diseases societies.

 

  • Professor Jeffrey Almond, Visiting Professor of Microbiology, Oxford University, United Kingdom

Jeffrey Almond is a Visiting Professor at the Sir William Dunn School of Pathology, University of Oxford and at the Department of Microbiology, University of Reading. He is also an Oxford Martin Fellow with the Oxford Martin Programme on Vaccines. Previously (1999-2014) he was Vice President and Global Head of Research and External R&D at Sanofi Pasteur, the vaccine division of the Sanofi group, based in Lyon France. There he was responsible for a portfolio of vaccine projects across infectious diseases and cancer, and for establishing and managing R&D partnerships with Academia and Biotech companies relevant to the commercial interests of Sanofi Pasteur. Prior to joining Sanofi, Jeffrey Almond spent most of his career in the UK. He was lecturer at the University of Leicester from 1979-85 and Professor of Microbiology and Head of the School of Animal and Microbial Sciences at the University of Reading 1985-99. He has served on numerous national and international committees including being a member of Council of the MRC and the UK Spongiform Encephalopathies Advisory Committee. Previously he has held senior officer positions in several learned societies including the International Union of Microbiological Societies and the Academy of Medical Sciences. Professor Almond is currently chair of the Scientific Advisory Board of the Pirbright Institute and is a member of several scientific advisory boards both in the public and private sectors in Europe, the UK, India and the USA.

 

  • Dr. Delon Human, Health Diplomats & South African Medical Association, Switzerland & South Africa

Delon Human is president of Health Diplomats, a global health consulting group facilitating innovation, increased access to care and subspecializing in harm reduction policy, science and products in the food, alcohol and tobacco sectors.

Previously, Human served as secretary- general and CEO of the World Medical Association (WMA), secretary-general of the International Food and Beverage Alliance, secretary-general of the African Harm Reduction Alliance, and adviser to the World Health Organization director-general and the U.N. secretary-general. In the field of research ethics, he oversaw the review of the Declaration of Helsinki for the WMA. He has chaired several scientific advisory boards, including a project to develop a COVID-19 vaccine candidate by a biopharmaceutical company.

Human holds qualifications in medicine, child health and business studies.

 

  • Professor David M. Salisbury, Associate Fellow, Global Health Programme, Royal Institute for International Affairs, Chatham House, London & Chair, WHO Global Commission for Certification of Polio Eradication, United Kingdom

Professor David Salisbury was Director of Immunisation at the Department of Health, London, until 2014; he was responsible for the national immunisation programme.

Professor Salisbury continues to work extensively with the World Health Organization on the Global Programme for Vaccines. He was the Chair of the WHO Strategic Advisory Group of Experts on Vaccines from 2005 to 2010. He is Chair of the Global Commission for Certification of Poliomyelitis Eradication, Chair of the Board of the Edward Jenner Vaccine Foundation and a Trustee for the Sabin Vaccine Institute.

Professor Salisbury was made a Companion of the Order of the Bath in the Queen’s Birthday Honours, 2001, for his services to immunisation. He is an Associate Fellow at the Centre on Global Health Security, Royal Institute of International Affairs, Chatham House, London.

 

  • Professor Alan Boyd, FFPM and Immediate Past President, FPM, United Kingdom

Professor Boyd is a Fellow and immediate Past- President of the Faculty of Pharmaceutical Medicine and an Honorary Professor at Birmingham University, where he graduated from. Joined the pharmaceutical industry in 1984 working for Glaxo and then AstraZeneca and became the Global Head of Medical Research. In 1999 established Ark Therapeutics Ltd, specialising in gene therapy. In 2005, founded Boyd Consultants, supporting early stage life-science companies and universities with development. He has brought several medicines to market across many therapeutic areas, including gene therapies. In 2018, awarded a ‘Queens Award for Enterprise’ for the global work he had done supporting the development of gene therapies.

This webinar is free to attend

  • BOOKINGS ARE NOW CLOSED

See our Terms & Conditions for booking and please note our privacy policy.

Joining instructions will be sent to attendees no earlier than Tuesday 30 June 2020.

 

If you have any queries, please email fpm@fpm.org.uk.

To find out about sponsorship opportunities for this series please email Will Strange at w.strange@fpm.org.uk